CoChat
Sign Up
Cited by 109Estrogen and related hormone effectsBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Letrozole: A Review of its Use in Postmenopausal Women with Advanced Breast Cancer

Lamb, Harriet M., Adkins, Julie C.·1998·Drugs
DOI 10.2165/00003495-199856060-00020
Open this paper in CoChat — free account

Abstract

Unlabelled Letrozole is an oral reversible nonsteroidal aromatase inhibitor. Clinical tracer studies show that it inhibits peripheral aromatase by over 98% and suppresses blood and urinary estrogen levels by over 95% after 2 weeks of treatment in postmenopausal women. Letrozole also significantly inhibits intratumoral aromatase in vivo. The action of letrozole appears to be selective for aromatase; long term administration did not affect basal levels of 17 alpha-hydroxyprogesterone or aldosterone, although slight decreases in cortisol levels were observed in 2 studies, these did not appear to be clinically significant. In 2 phase IIb/III trials, letrozole 2.5 mg/day achieved objective response rates of 19.5 and 23.6% which were sustained for a median duration of 24 and 33 months, respectively. The median duration of response compared favourably with both comparator agents, aminoglutethimide and megestrol (15 and 18 months, respectively), as did objective response rates (12.4 and 16.4%). Letrozole 2.5 mg/day was associated with an increase in median survival time of 8 and 3 months compared with aminoglutethimide and megestrol, respectively. According to analyses of overall function, letrozole 2.5 mg/day was significantly superior to both comparators with respect to duration of response and aminoglutethimide with respect to survival. Letrozole has a good short term tolerability profile. The adverse events reported most commonly in association with letrozole 2.5 mg/day in the 2 phase IIb/III trials were headache (1.1 and 7%), nausea (6 and 10.3%), fatigue (3.2 and 5%), hot flushes (4.9 and 5%) and peripheral oedema (6%). Events were usually mild to moderate in severity; adverse events necessitated discontinuation of treatment in 3% of letrozole 2.5 mg/day recipients.Conclusions Letrozole, in common with vorozole and anastrozole, offers greater selectivity and potency of aromatase inhibition than the prototype aromatase inhibitor, aminoglutethimide, and can be administered once daily. Available clinical data suggest that letrozole achieves a significantly longer duration of response than megestrol and aminoglutethimide and longer overall survival than aminoglutethimide. However, direct comparisons are required to distinguish between the newer aromatase inhibitors. For this reason, letrozole should be recommended as a second-line treatment in postmenopausal women with advanced breast cancer whose disease has progressed on or failed to respond to antiestrogen therapy.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-199856060-00020

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Lamb, H. M., & Adkins, J. C.
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
1998
Volume
56
Issue
6
Pages
1125-1140
ISSN
0012-6667 (ISSN-L)
DOI
10.2165/00003495-199856060-00020
OpenAlex
W3192809827
Cited by
109
References
42
Citations by year
2026: 1 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 11 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 1 · 2012: 5
FWCI
0.76
Type
journal article
Language
en
Open access
closed
Locations
Drugs (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
letrozole, aromatase inhibitors, breast cancer, postmenopausal women, estrogen suppression, aminoglutethimide, megestrol, duration of response, survival, tolerability, adverse events, hot flashes, peripheral edema, anastrozole, vorozole, 17-hydroxyprogesterone, aldosterone, cortisol

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review